Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging

OBJECTIVE: To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial SpA (r-axSpA) and elevated or normal/low baseline inflammation measured by serum CRP or spinal MRI using data from two randomized, double-blind, placebo (PBO)-controlled phase III trials. METHODS: Bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Maksymowych, Walter P, Bolce, Rebecca, Gallo, Gaia, Seem, Emily, Geneus, Vladimir J, Sandoval, David M, Østergaard, Mikkel, Tada, Kurisu, Baraliakos, Xenofon, Deodhar, Atul, Gensler, Lianne S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629340/
https://www.ncbi.nlm.nih.gov/pubmed/35188180
http://dx.doi.org/10.1093/rheumatology/keac104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629340/
https://www.ncbi.nlm.nih.gov/pubmed/35188180
http://dx.doi.org/10.1093/rheumatology/keac104

Ejemplares similares